全文获取类型
收费全文 | 190178篇 |
免费 | 16671篇 |
国内免费 | 10640篇 |
专业分类
耳鼻咽喉 | 2130篇 |
儿科学 | 2919篇 |
妇产科学 | 1654篇 |
基础医学 | 18991篇 |
口腔科学 | 3425篇 |
临床医学 | 21851篇 |
内科学 | 27078篇 |
皮肤病学 | 3189篇 |
神经病学 | 8951篇 |
特种医学 | 8299篇 |
外国民族医学 | 45篇 |
外科学 | 20131篇 |
综合类 | 34188篇 |
现状与发展 | 43篇 |
一般理论 | 15篇 |
预防医学 | 16060篇 |
眼科学 | 3807篇 |
药学 | 20010篇 |
192篇 | |
中国医学 | 11062篇 |
肿瘤学 | 13449篇 |
出版年
2024年 | 562篇 |
2023年 | 2188篇 |
2022年 | 5692篇 |
2021年 | 8050篇 |
2020年 | 6073篇 |
2019年 | 5037篇 |
2018年 | 5329篇 |
2017年 | 5585篇 |
2016年 | 5593篇 |
2015年 | 8630篇 |
2014年 | 10958篇 |
2013年 | 11586篇 |
2012年 | 16961篇 |
2011年 | 17757篇 |
2010年 | 13555篇 |
2009年 | 11403篇 |
2008年 | 13032篇 |
2007年 | 12651篇 |
2006年 | 11659篇 |
2005年 | 10226篇 |
2004年 | 7488篇 |
2003年 | 6821篇 |
2002年 | 5810篇 |
2001年 | 3507篇 |
2000年 | 2727篇 |
1999年 | 1852篇 |
1998年 | 1117篇 |
1997年 | 1145篇 |
1996年 | 769篇 |
1995年 | 703篇 |
1994年 | 602篇 |
1993年 | 375篇 |
1992年 | 360篇 |
1991年 | 321篇 |
1990年 | 235篇 |
1989年 | 177篇 |
1988年 | 145篇 |
1987年 | 126篇 |
1986年 | 112篇 |
1985年 | 65篇 |
1984年 | 79篇 |
1983年 | 43篇 |
1982年 | 42篇 |
1981年 | 39篇 |
1980年 | 35篇 |
1979年 | 26篇 |
1978年 | 31篇 |
1974年 | 21篇 |
1973年 | 23篇 |
1972年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
目的:探究金水宝片联合依诺肝素对维持性血液透析患者血脂代谢的影响。方法:选取2018年12月至2019年3月马鞍山十七冶医院血液净化中心进行透析的患者154例作为研究对象,根据用药不同分为对照组和观察组,每组77例。对照组常规应用依诺肝素抗凝,观察组在对照组抗凝基础上加用金水宝片,各组均干预3个月,比较2组患者血脂变化及持续血液透析并发症发生情况。结果:治疗后,观察组患者三酰甘油、总胆固醇及低密度脂蛋白胆固醇水平下降,高密度脂蛋白胆固醇升高,与治疗前比较差异均有统计学意义(P<0.05),与对照组治疗后比较,差异有统计学意义(P<0.05);观察组总并发症发生率明显低于对照组,2组比较差异有统计学意义(P<0.05);2组患者维持性血液透析不良反应发生率均较低,组间比较差异无统计学意义(P>0.05)。结论:金水宝片联合依诺肝素有助于改善维持性血液透析患者血脂代谢水平,降低维持性血液透析相关并发症,值得临床推广应用。 相似文献
3.
Kazunori Aizawa Takeshi Hanaoka Hiroki Kasai Kaoru Kogashi Setsuo Kumazaki Jun Koyama Hiroshi Tsutsui Yoshikazu Yazaki Noboru Watanabe Osamu Kinoshita Uichi Ikeda 《Hypertension research》2006,29(2):123-128
The phosphodiesterase-5 (PDE-5) inhibitor, sildenafil, has been reported to produce sustained pulmonary vasodilatation in patients with pulmonary hypertension (PH). Recently, vardenafil, a more potent and selective PDE-5 inhibitor than sildenafil, has been approved for the treatment of erectile dysfunction. However, the long-term effects of oral vardenafil in patients with PH are unknown. We studied five consecutive patients with PH; one with primary pulmonary hypertension, two with chronic pulmonary thromboembolism, one with Eisenmenger syndrome (ventricular septal defect) and one with secondary pulmonary hypertension after a ventricular septal defect closure operation. In an acute hemodynamic trial, vardenafil (5 mg) significantly decreased both the pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR) with an increase in cardiac output. In a chronic hemodynamic trial, the maintenance dose of vardenafil (10 to 15 mg) for 3 months significantly decreased the PVR, but not the SVR, with a 20.7% reduction of the PVR/ SVR ratio. Plasma brain natriuretic peptide (BNP) levels were also significantly decreased after 3 months. This pilot study demonstrates that long-term oral vardenafil therapy may be a safe and effective treatment for patients with PH. 相似文献
4.
Jun Agata Nobuyuki Ura Hideaki Yoshida Yasuyuki Shinshi Haruki Sasaki Masaya Hyakkoku Shinya Taniguchi Kazuaki Shimamoto 《Hypertension research》2006,29(11):865-874
Angiotensin II receptor blockers (ARBs) are widely used for the treatment of hypertension. It is believed that treatment with an ARB increases the level of plasma angiotensin II (Ang II) because of a lack of negative feedback on renin activity. However, Ichikawa (Hypertens Res 2001; 24: 641-646) reported that long-term treatment of hypertensive patients with olmesartan resulted in a reduction in plasma Ang II level, though the mechanism was not determined. It has been reported that angiotensin 1-7 (Ang-(1-7)) potentiates the effect of bradykinin and acts as an angiotensin-converting enzyme (ACE) inhibitor. It is known that ACE2, which was discovered as a novel ACE-related carboxypeptidase in 2000, hydrolyzes Ang I to Ang-(1-9) and also Ang II to Ang-(1-7). It has recently been reported that olmesartan increases plasma Ang-(1-7) through an increase in ACE2 expression in rats with myocardial infarction. We hypothesized that over-expression of ACE2 may be related to a reduction in Ang II level and the cardioprotective effect of olmesartan. Administration of 0.5 mg/kg/day of olmesartan for 4 weeks to 12-week-old stroke-prone spontaneously hypertensive rats (SHRSP) significantly reduced blood pressure and left ventricular weight compared to those in SHRSP given a vehicle. Co-administration of olmesartan and (D-Ala7)-Ang-(1-7), a selective Ang-(1-7) antagonist, partially inhibited the effect of olmesartan on blood pressure and left ventricular weight. Interestingly, co-administration of (D-Ala7)-Ang-(1-7) with olmesartan significantly increased the plasma Ang II level (453.2+/-113.8 pg/ml) compared to olmesartan alone (144.9+/-27.0 pg/ml, p<0.05). Moreover, olmesartan significantly increased the cardiac ACE2 expression level compared to that in Wistar Kyoto rats and SHRSP treated with a vehicle. Olmesartan significantly improved cardiovascular remodeling and cardiac nitrite/ nitrate content, but co-administration of olmesartan and (D-Ala7)-Ang-(1-7) partially reversed this anti-remodeling effect and the increase in nitrite/nitrate. These findings suggest that olmesartan may exhibit an ACE inhibitory action in addition to an Ang II receptor blocking action, prevent an increase in Ang II level, and protect cardiovascular remodeling through an increase in cardiac nitric oxide production and endogenous Ang-(1-7) via over-expression of ACE2. 相似文献
5.
药物依赖心理治疗的基本技术——动机强化治疗的理论与技术 总被引:3,自引:1,他引:2
赵敏 《中国药物滥用防治杂志》2006,12(6):311-314
现代科学证实,药物依赖(吸毒)是一种慢性复发性脑疾病,具有复杂的心理学、生物学与社会学病因机制,应采取躯体、心理、社会康复等综合治疗的模式来治疗药物依赖导致的各种相关问题,对药物依赖的治疗过程是一个长期的、复杂的过程。脱毒只是戒毒治疗的前提,除海洛因等阿片类药物 相似文献
6.
7.
Vincent Chung Liang Liu Zhaoxiang Bian Zhongzhen Zhao Wai Leuk Fong Wan Fung Kum Jing Gao Min Li 《Movement disorders》2006,21(10):1709-1715
The objective of this study is to assess the efficacy and safety of herbal medicines (HMs), as a monotherapy or adjunct therapy, compared to placebo or conventional approaches in the treatment of idiopathic Parkinson's disease (PD). We conducted a systematic review of randomized controlled trials from both conventional and alternative medicine sources. Outcome measures were overall improvement, quality of life, reduction of levodopa dose, and adverse events. Nine studies were included, each testing a different HM. Six of the trials had limited internal validity due to major flaws in design, including the lack of proper randomization; insufficient blinding; unclear inclusive criteria in terms of diagnostic criteria, baseline staging, and duration of disease; lack of proper sample size calculation; and insufficient data analysis. Imbalances in gender and ethnicity among the patients in the included trials were observed. No major adverse events emerged, and no specific pattern was detected from the trials describing such data. In addition to major methodological defects, heterogeneity in (1) HM tested, (2) control treatment, and (3) outcome measure hindered in-depth data analysis and synthesis. Current evidence is insufficient to evaluate the efficacy and safety of various HMs. Further studies with improved trial design and reporting, with assessment on cost-effectiveness, quality of life, and qualitative data are warranted. 相似文献
8.
9.
Abstract: Background: Few studies have examined in depth the labor progression of multiparas to determine if there is any additional impact of being parous beyond the first birth. The objective of this study was to determine the effect of parity on labor progression in contemporary obstetric practice. Methods: Our sample consisted of all low‐risk women who delivered a term, live‐born infant from January 2002 to March 2004 at a single institution in Delaware, United States (n = 5,589). The median duration of labor by each centimeter of cervical dilation was computed for parity = 0 (n = 2,645); parity = 1 (n = 1,839); parity = 2 (n = 750); and parity = 3 + (n = 355). Results: Multiparas had a significantly faster labor progression from 4 to 10 cm (293, 300, and 313 min, respectively, for parity = 1, parity = 2, and parity = 3 +), compared with nulliparas (383 min for parity = 0), as well as a shorter second stage of labor. However, no significant differences were found in duration of the active phase or the second stage of labor among multiparas. Conclusions: Additional childbearing appears to have no effect of on the progression of labor among multiparous subgroups. The difference in duration of the active phase between nulliparas and multiparas is substantially smaller in a contemporary population. (BIRTH 33:1 March 2006) 相似文献
10.
灰关联分析应用于因素分析时关联度指标的改进 总被引:8,自引:1,他引:7
本文指出在应用灰关联分析进行因素分析时传统的关联度计算方法的不足,并提出采用新的关联度指标来表示因素之间的关联关系,同时给出了实例介绍计算方法。 相似文献